Abstract
Sunitinib and Sorafenib are both effective angiogenetic inhibitors for the treatment of renal cell carcinoma. With these drugs of a new class of chronic therapy is performed. During chronic treatment, the inherent side effects may necessitate stopping the application of these drugs thus preventing the required effective therapy. Most of the effects can be avoided or attenuated by prophylaxis. In this paper the published data are reviewed and added with our experience in 138 patients over up to two and a half years.
Publication types
-
Case Reports
-
Comparative Study
-
Review
MeSH terms
-
Adult
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Benzenesulfonates / adverse effects*
-
Benzenesulfonates / therapeutic use
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Drug Eruptions / etiology*
-
Female
-
Gastrointestinal Diseases / chemically induced*
-
Humans
-
Indoles / adverse effects*
-
Indoles / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
-
Pyrroles / adverse effects*
-
Pyrroles / therapeutic use
-
Sorafenib
-
Sunitinib
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Benzenesulfonates
-
Indoles
-
Phenylurea Compounds
-
Pyridines
-
Pyrroles
-
Niacinamide
-
Sorafenib
-
Sunitinib